UBS Group Trims Jazz Pharmaceuticals (NASDAQ:JAZZ) Target Price to $113.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price reduced by UBS Group from $117.00 to $113.00 in a research report report published on Tuesday morning, Benzinga reports. They currently have a neutral rating on the specialty pharmaceutical company’s stock.

JAZZ has been the topic of several other research reports. StockNews.com raised Jazz Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Thursday, June 27th. The Goldman Sachs Group initiated coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 5th. They issued a buy rating and a $169.00 price objective on the stock. Piper Sandler lifted their price objective on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the stock an overweight rating in a report on Wednesday, March 20th. HC Wainwright reissued a buy rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, May 3rd. Finally, Truist Financial reiterated a buy rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of Moderate Buy and a consensus target price of $188.62.

Jazz Pharmaceuticals Stock Down 1.5 %

JAZZ stock opened at $103.53 on Tuesday. The company has a current ratio of 2.27, a quick ratio of 1.90 and a debt-to-equity ratio of 1.38. Jazz Pharmaceuticals has a 12 month low of $102.86 and a 12 month high of $146.70. The stock has a market capitalization of $6.53 billion, a P/E ratio of 21.35, a price-to-earnings-growth ratio of 1.61 and a beta of 0.58. The firm has a 50-day moving average price of $108.62 and a 200-day moving average price of $116.26.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.53 by ($1.55). The firm had revenue of $901.98 million for the quarter, compared to the consensus estimate of $938.99 million. Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. As a group, equities research analysts anticipate that Jazz Pharmaceuticals will post 15.35 EPS for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In other news, EVP Neena M. Patil sold 5,000 shares of the firm’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $109.65, for a total value of $548,250.00. Following the transaction, the executive vice president now owns 36,629 shares of the company’s stock, valued at $4,016,369.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.20% of the stock is currently owned by company insiders.

Institutional Trading of Jazz Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rise Advisors LLC raised its position in shares of Jazz Pharmaceuticals by 2,255.6% during the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock valued at $26,000 after buying an additional 203 shares in the last quarter. GAMMA Investing LLC boosted its stake in Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after acquiring an additional 116 shares in the last quarter. Cape Investment Advisory Inc. raised its stake in Jazz Pharmaceuticals by 14,600.0% in the fourth quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock valued at $36,000 after buying an additional 292 shares during the last quarter. Assetmark Inc. increased its holdings in shares of Jazz Pharmaceuticals by 37.1% during the fourth quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company’s stock valued at $54,000 after acquiring an additional 119 shares in the last quarter. Finally, Headinvest LLC acquired a new position in shares of Jazz Pharmaceuticals in the 3rd quarter valued at $56,000. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.